What is the risk of hyponatremia with mirtazapine, particularly in older adults, women, and patients taking diuretics or selective serotonin reuptake inhibitors (SSRIs)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Mirtazapine Risk of Hyponatremia

Mirtazapine carries a moderate risk of hyponatremia (3.26% incidence), which is significantly lower than SSRIs and SNRIs, making it a safer alternative for patients at high risk of this electrolyte disorder.

Risk Profile and Incidence

The FDA label explicitly warns that hyponatremia may occur with mirtazapine, including cases with serum sodium <110 mmol/L 1. A systematic review quantified the incidence at 3.26% (95% CI 3.06-3.45%) 2, which is substantially lower than SSRIs (9.81%) and SNRIs (10.40%) 3. The underlying mechanism appears to be syndrome of inappropriate antidiuretic hormone secretion (SIADH) 1, 2.

High-Risk Populations

Elderly patients are at greatest risk. The FDA label specifically states that elderly patients may be at greater risk of developing hyponatremia 1. Published case series demonstrate that mirtazapine-induced hyponatremia occurs predominantly in patients >60 years of age, with a mean onset of 6.5 days after initiation and doses as low as 7.5 mg daily 4. The mean sodium nadir was 117.2 mEq/L, with recovery taking approximately 11 days after discontinuation 4.

Women are disproportionately affected. Among reported cases, 71.4% occurred in female patients 2, with postmenopausal women representing a particularly vulnerable subgroup 5.

Patients taking diuretics face compounded risk. The FDA label explicitly warns that patients taking diuretics are at greater risk 1. While the evidence provided focuses on thiazide diuretics with SSRIs (showing OR 1.24-1.27 for hyponatremia) 6, the general principle of additive risk applies to mirtazapine as well, given its SIADH mechanism.

Comparative Safety

Mirtazapine is significantly safer than SSRIs and SNRIs. A 2026 meta-analysis of 2,115,187 geriatric patients found that mirtazapine was associated with significantly lower risks of both any hyponatremia (RR = 0.61,95% CI: 0.39-0.61, P = 0.031) and clinically relevant hyponatremia (RR = 0.49,95% CI: 0.39-0.61, P < 0.001) compared with SSRIs 3. This makes mirtazapine a preferred option when hyponatremia risk is a concern.

Newly initiated SSRIs carry particularly high risk (citalopram OR 5.50, sertraline OR 4.96, venlafaxine OR 5.28), while mirtazapine showed only moderate risk (OR 2.54) 7. Importantly, ongoing treatment with mirtazapine showed no increased risk compared to controls 7.

Clinical Monitoring Strategy

Check baseline sodium before initiating mirtazapine in high-risk patients (elderly, women, those on diuretics, volume-depleted patients) 1.

Monitor sodium levels within 1-2 weeks of initiation in high-risk patients, as most cases occur within the first 6.5 days (range up to 34 days) 2, 4.

Watch for clinical manifestations: confusion (57%), somnolence (42%), and altered speech (28%) are the most common presentations 2. More severe symptoms include hallucination, syncope, seizure, coma, respiratory arrest, and death 1.

Management of Hyponatremia

Discontinue mirtazapine immediately if symptomatic hyponatremia develops 1. Recovery typically occurs within 7-11 days after cessation 4.

Institute appropriate medical intervention for symptomatic hyponatremia, which may include hypertonic saline for severe cases (sodium <120-125 mmol/L) 1.

Common Pitfalls

  • Don't assume all antidepressants carry equal hyponatremia risk. Mirtazapine is demonstrably safer than SSRIs/SNRIs 3, 7.
  • Don't overlook low-dose risk. Hyponatremia has occurred with mirtazapine doses as low as 7.5 mg daily 4.
  • Don't forget the temporal window. Most cases occur within the first 2 weeks, but can occur up to 34 days after initiation 2, 4.
  • Don't ignore volume status. Volume-depleted patients are at greater risk 1.

Clinical Decision Algorithm

For patients requiring antidepressant therapy:

  • Low hyponatremia risk (young, male, no diuretics, normal volume status): Any appropriate antidepressant
  • Moderate risk (elderly OR female OR on diuretics): Prefer mirtazapine over SSRIs/SNRIs
  • High risk (elderly + female + diuretics, or history of hyponatremia): Strongly prefer mirtazapine; check baseline sodium; monitor at 1-2 weeks
  • Very high risk (prior SIADH, sodium <135 at baseline): Consider non-serotonergic alternatives; if mirtazapine used, weekly sodium monitoring for first month

References

4
Research

Mirtazapine associated with profound hyponatremia: two case reports.

The American journal of geriatric pharmacotherapy, 2008

Related Questions

Which selective serotonin reuptake inhibitor (SSRI) is associated with the lowest risk of drug‑induced hyponatremia?
Can mirtazapine cause syndrome of inappropriate antidiuretic hormone secretion (SIADH)?
Which antidepressant medications can cause hyponatremia?
Can fenofibrate, citalopram, metformin, Prempro (conjugated estrogen and medroxyprogesterone acetate), magnesium oxide, zinc glycinate, vitamin C, docusate sodium, or ergocalciferol (vitamin D2) cause hyponatremia?
In a 78-year-old woman taking fluoxetine 10 mg daily and mirtazapine 15 mg nightly who is markedly drowsy and has hyponatraemia (serum sodium 133 mmol/L), mildly elevated aspartate aminotransferase (AST 43 U/L), and severe thrombocytopenia (platelet count 31 ×10⁹/L), what is the appropriate initial management?
For an adult with markedly elevated triglycerides (≥500 mg/dL) and no contraindications, which is preferred: icosapent ethyl (Viscepa), mixed omega‑3 ethyl esters (Omacor), or fenofibrate (Lipanthyl)?
What is the pathophysiology of muscle wasting in patients with diabetes?
Is radiotherapy indicated for a residual 10‑centimeter paraspinal ganglioneuroma?
Is it appropriate to start doxycycline as post‑exposure prophylaxis one month after flood exposure?
When is it appropriate to combine ambroxol with N‑acetylcysteine, and what are the recommended dosages and contraindications?
What is the intramuscular dosing of Unasyn (ampicillin + sulbactam) for adults and pediatric patients, including adjustments for renal impairment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.